Is BLTE or VTRS more profitable?

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Viatris -2.79% 20.02% 8.02%

Does the media refer more to NBIX or BLTE?

In the previous week, Belite Bio had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Belite Bio and 20 mentions for Neurocrine Biosciences. Belite Bio's average media sentiment score of 0.72 beat Neurocrine Biosciences' score of 0.62 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer JAZZ or BLTE?

In the previous week, Belite Bio had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 21 mentions for Belite Bio and 18 mentions for Jazz Pharmaceuticals. Belite Bio's average media sentiment score of 0.72 beat Jazz Pharmaceuticals' score of 0.51 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELAN or BLTE?

In the previous week, Elanco Animal Health had 3 more articles in the media than Belite Bio. MarketBeat recorded 24 mentions for Elanco Animal Health and 21 mentions for Belite Bio. Elanco Animal Health's average media sentiment score of 0.85 beat Belite Bio's score of 0.72 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 9 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CORT or BLTE?

In the previous week, Belite Bio had 11 more articles in the media than Corcept Therapeutics. MarketBeat recorded 21 mentions for Belite Bio and 10 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.11 beat Belite Bio's score of 0.72 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Belite Bio (BLTE) Competitors

$160.69 -5.59 (-3.36%)

As of 01:01 PM Eastern

Compare

BLTE vs. VTRS, NBIX, JAZZ, ELAN, and CORT

Should you buy Belite Bio stock or one of its competitors? Belite Bio's main competitors and comparable companies include Viatris (VTRS), Neurocrine Biosciences (NBIX), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), and Corcept Therapeutics (CORT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Belite Bio compare to Viatris?

Belite Bio (NASDAQ:BLTE) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Belite Bio has higher earnings, but lower revenue than Viatris. Belite Bio is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Viatris	$14.30B	1.30	-$3.51B	-$0.36	N/A

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Viatris	-2.79%	20.02%	8.02%

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Belite Bio presently has a consensus target price of $205.80, suggesting a potential upside of 26.86%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 8.33%. Given Belite Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Belite Bio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Belite Bio has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

In the previous week, Belite Bio had 20 more articles in the media than Viatris. MarketBeat recorded 21 mentions for Belite Bio and 1 mentions for Viatris. Viatris' average media sentiment score of 1.89 beat Belite Bio's score of 0.72 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
Belite Bio	Positive
Viatris	Very Positive

Summary

Belite Bio and Viatris tied by winning 8 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

In the previous week, Belite Bio had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Belite Bio and 20 mentions for Neurocrine Biosciences. Belite Bio's average media sentiment score of 0.72 beat Neurocrine Biosciences' score of 0.62 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has a net margin of 20.91% compared to Belite Bio's net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Belite Bio	N/A	-13.14%	-12.88%

Neurocrine Biosciences has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.39	$478.60M	$6.82	22.24
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neurocrine Biosciences currently has a consensus target price of $200.86, suggesting a potential upside of 32.41%. Belite Bio has a consensus target price of $205.80, suggesting a potential upside of 26.86%. Given Neurocrine Biosciences' higher probable upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Neurocrine Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the broader market.

Summary

Neurocrine Biosciences beats Belite Bio on 11 of the 14 factors compared between the two stocks.

How does Belite Bio compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Belite Bio's net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Belite Bio	N/A	-13.14%	-12.88%

In the previous week, Belite Bio had 3 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 21 mentions for Belite Bio and 18 mentions for Jazz Pharmaceuticals. Belite Bio's average media sentiment score of 0.72 beat Jazz Pharmaceuticals' score of 0.51 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Jazz Pharmaceuticals currently has a consensus target price of $272.89, suggesting a potential upside of 12.27%. Belite Bio has a consensus target price of $205.80, suggesting a potential upside of 26.86%. Given Belite Bio's higher probable upside, analysts clearly believe Belite Bio is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Belite Bio has lower revenue, but higher earnings than Jazz Pharmaceuticals. Belite Bio is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.70	-$356.15M	$14.50	16.76
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

Jazz Pharmaceuticals beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Elanco Animal Health presently has a consensus price target of $29.09, suggesting a potential upside of 24.93%. Belite Bio has a consensus price target of $205.80, suggesting a potential upside of 26.86%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Belite Bio has lower revenue, but higher earnings than Elanco Animal Health. Belite Bio is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.47	-$232M	-$0.41	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Elanco Animal Health has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, meaning that its share price is 222% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Belite Bio	N/A	-13.14%	-12.88%

In the previous week, Elanco Animal Health had 3 more articles in the media than Belite Bio. MarketBeat recorded 24 mentions for Elanco Animal Health and 21 mentions for Belite Bio. Elanco Animal Health's average media sentiment score of 0.85 beat Belite Bio's score of 0.72 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	9 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Elanco Animal Health beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Belite Bio had 11 more articles in the media than Corcept Therapeutics. MarketBeat recorded 21 mentions for Belite Bio and 10 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.11 beat Belite Bio's score of 0.72 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a net margin of 6.52% compared to Belite Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Belite Bio	N/A	-13.14%	-12.88%

Corcept Therapeutics has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$830.81M	14.73	$99.65M	$0.42	269.54
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, indicating that its stock price is 222% less volatile than the broader market.

Corcept Therapeutics currently has a consensus price target of $119.17, indicating a potential upside of 5.27%. Belite Bio has a consensus price target of $205.80, indicating a potential upside of 26.86%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts plainly believe Belite Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Corcept Therapeutics beats Belite Bio on 11 of the 15 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLTE vs. The Competition

Export

Metric	Belite Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.49B	$11.72B	$6.98B	$13.03B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-63.97	783.86	269.56	25.24
Price / Sales	N/A	748.12	596.34	100.74
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	7.90	10.74	13.02	6.32
Net Income	-$77.61M	$2.78B	$3.45B	$347.92M
7 Day Performance	-0.51%	-0.29%	0.69%	0.91%
1 Month Performance	10.59%	-0.17%	1.32%	0.89%
1 Year Performance	135.17%	160.95%	66.86%	20.28%

Belite Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLTE Belite Bio	3.9502 of 5 stars	$160.69 -3.4%	$205.80 +28.1%	+132.3%	$6.44B	N/A	N/A	10	Trending News Analyst Forecast
VTRS Viatris	2.6284 of 5 stars	$17.59 -0.3%	$17.50 -0.5%	+54.1%	$20.44B	$14.30B	N/A	30,000	Positive News
NBIX Neurocrine Biosciences	4.9877 of 5 stars	$167.72 +0.9%	$201.50 +20.1%	+14.6%	$16.86B	$3.37B	24.59	2,000	Analyst Downgrade
JAZZ Jazz Pharmaceuticals	4.1011 of 5 stars	$249.21 -0.9%	$267.37 +7.3%	+109.9%	$15.68B	$4.44B	N/A	2,890	Analyst Forecast
ELAN Elanco Animal Health	4.3645 of 5 stars	$25.65 -0.3%	$28.73 +12.0%	+26.3%	$12.76B	$4.72B	N/A	9,400	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLTE) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, NBIX, JAZZ, ELAN, and CORT

How does Belite Bio compare to Viatris?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Summary

How does Belite Bio compare to Elanco Animal Health?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, NBIX, JAZZ, ELAN, and CORT

How does Belite Bio compare to Viatris?

Which has preferable earnings & valuation, BLTE or VTRS?

Is BLTE or VTRS more profitable?

Do institutionals & insiders hold more shares of BLTE or VTRS?

Do analysts recommend BLTE or VTRS?

Which has more volatility & risk, BLTE or VTRS?

Does the media refer more to BLTE or VTRS?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Does the media refer more to NBIX or BLTE?

Is NBIX or BLTE more profitable?

Which has stronger valuation and earnings, NBIX or BLTE?

Do institutionals & insiders hold more shares of NBIX or BLTE?

Do analysts recommend NBIX or BLTE?

Which has more risk and volatility, NBIX or BLTE?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Which has more risk & volatility, JAZZ or BLTE?

Is JAZZ or BLTE more profitable?

Does the media prefer JAZZ or BLTE?

Do institutionals and insiders hold more shares of JAZZ or BLTE?

Do analysts rate JAZZ or BLTE?

Which has better earnings & valuation, JAZZ or BLTE?

Summary

How does Belite Bio compare to Elanco Animal Health?

Do analysts recommend ELAN or BLTE?

Which has stronger valuation and earnings, ELAN or BLTE?

Which has more risk and volatility, ELAN or BLTE?

Is ELAN or BLTE more profitable?

Does the media refer more to ELAN or BLTE?

Do institutionals & insiders hold more shares of ELAN or BLTE?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Do insiders and institutionals have more ownership in CORT or BLTE?

Does the media refer more to CORT or BLTE?

Is CORT or BLTE more profitable?

Which has preferable earnings & valuation, CORT or BLTE?

Which has more volatility and risk, CORT or BLTE?

Do analysts prefer CORT or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools